Clinical trials: Bronchus Tumour
Carcinoma, Non-Small-Cell Lung, Lung Neoplasms
Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer
The purpose of this study is to learn whether HKI-272 is safe and effective in treating non-small cell lung cancer.
- Trial name
- NCT00266877
- Testing
- HKI-272
- Where
- 19 sites in United States, France and 3 more
- Volunteers
- 172 people
- Sponsor
- Puma Biotechnology, Inc.
Locally Advanced or Metastatic NSCLC
Real World Study in Locally Advanced or Metastatic NSCLC Patients, Progressed From First-line EGFR-TKI Therapy
To estimate parameters associated with treatment patterns and related clinical outcomes.Including physician reported PFS and OS.
- Trial name
- PISCES (NCT04207775)
- Where
- 16 sites in China
- Volunteers
- 300 people
- Sponsor
- AstraZeneca
Bronchial Neoplasm Benign
Survivin and Fibulin-3 in Benign and Malignant Respiratory Diseases
Purpose: Survivin is a common member of the inhibitors of the apoptosis protein (IAP) family with a dual role in promoting cell proliferation and preventing apoptosis.
- Trial name
- NCT04413292
- Testing
- ELISA assays and Westren blot analysis of survivin and fibulin-3 expression
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- South Valley University
HER2-positive Breast Cancer, HER2-positive Biliary Tract Cancer
Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors
Phase I Dose Finding Study for GQ1001 in Patients with HER2-Positive Advanced Solid Tumors
- Conditions
- HER2-positive Breast Cancer, HER2-positive Biliary Tract Cancer, HER2-Positive Salivary Gland Carcinomas, HER2-Positive Advanced Solid Tumor
- Trial name
- NCT04450732
- Testing
- GQ1001
- Where
- 24 sites in United States, Australia and 1 more
- Volunteers
- 96 people
- Sponsor
- GeneQuantum Healthcare (Suzhou) Co., Ltd.
Lung Neoplasm Malignant
Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer
Neoadjuvant chemotherapy followed by surgery has been recommended as the standard treatment for locally advanced and resectable non-small cell lung cancer (NSCLC). However, its efficacy remains to be improved.
- Trial name
- NCT04973293
- Testing
- sintilimab, bevacizumab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Ruijin Hospital
Solid Tumor, Adult
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
This is a Phase 1 dose-finding study of FT538 in combination with monoclonal antibodies.
- Trial name
- NCT05069935
- Testing
- FT538, Cyclophosphamide, Fludarabine
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- Fate Therapeutics
Non-Small Cell Lung Cancer
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
The purpose of this phase II study is to find out what effects cabozantinib (XL184) has, good and/or bad, in patients whose tumors one of the following gene changes RET, ROS1, or NTRK fusion, or increased MET or AXL activity.
- Trial name
- NCT01639508
- Testing
- Cabozantinib
- Where
- 7 sites in United States
- Volunteers
- 86 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
NSCLC Stage IV, Limited Metastatic Disease
Combination of SABR and L19-IL2 in Patients With Stage IV Lung Cancer (ImmunoSABR)
This will be a phase II trial testing if the combination of SBRT and L19-IL2 improves the progression free survival in patients with limited metastatic non-small cell lung cancer (NSCLC).
- Trial name
- ImmunoSABR (NCT02735850)
- Testing
- L19-IL2, SBRT, No intervention
- Where
- Netherlands
- Sponsor
- Maastricht Radiation Oncology
Non-small Cell Lung Cancer
Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI
This is a Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study to evaluate the efficacy and safety of Toripalimab injection (JS001) or placebo combined with chemotherapy in Advanced Non-small Cell Lung…
- Trial name
- NCT03924050
- Testing
- TORIPALIMAB INJECTION(JS001 )
- Where
- 2 sites in China
- Volunteers
- 440 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Small Cell Lung Cancer, Carcinoma, Small Cell
Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage Small-Cell Lung Cancer
This proposed phase II trial will investigate weekly topotecan at a higher dose than was used in the previous trials in an attempt to achieve improved response rates and disease control without added toxicity.
- Trial name
- NCT00294190
- Testing
- Topotecan
- Where
- 13 sites in United States
- Volunteers
- 38 people
- Sponsor
- SCRI Development Innovations, LLC
Small Cell Lung Cancer
Patient-derived Organoid Drug Sensitivity Guided Treatment for Recurrent Small Cell Lung Cancer
This study plans to enroll 20 patients with recurrent small cell lung cancer. Patient-derived Organoid will be established, and drug sensitivity test will be conducted to intervene in the selection of clinical treatment plans.
- Trial name
- NCT06406660
- Testing
- Chemotherapy and targeted-therapy guided by organoid drug sensitivity test
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Henan Cancer Hospital
Non-Small Cell Lung Cancer
Noninvasive vs. Invasive Lung Evaluation
Tumor derived cell free DNA (cfDNA) is increasingly used in the clinic to obtain genotype information about lung cancer, but its concordance with concurrent tumor-derived sequenced data is not known.
- Trial name
- NILE (NCT03615443)
- Testing
- Guardant360
- Volunteers
- 306 people
- Sponsor
- Guardant Health, Inc.
Gastric Cancer Stage II, Non-small Cell Lung Cancer Stage II
Oncoxin® and Quality of Life in Cancer Patients
It is expected that additional support with certain micronutrients may improve prognosis, decrease the frequency of side effects and complications and maintain high relative dose intensity of anticancer treatments.
- Conditions
- Gastric Cancer Stage II, Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage III, Gastric Cancer Stage III
- Trial name
- NCT03550482
- Testing
- ONCOXIN®
- Where
- 9 sites in Kazakhstan, Russia
- Volunteers
- 133 people
- Sponsor
- Catalysis SL
Lung Cancer
FDG-PET/CT Scans in Patients With Stage IIIB or Stage IV NSCLC Undergoing Chemotherapy
RATIONALE: Diagnostic procedures, such as fludeoxyglucose F 18 (^18FDG) positron emission tomography (PET)/CT scans, may help doctors predict a patient's response to treatment and help plan the best treatment.
- Trial name
- ACRIN6678 (NCT00424138)
- Testing
- FDG
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- American College of Radiology Imaging Network
Non Small Cell Lung Cancer
Study of Nivolumab-Ipilimumab and cfDNA in Lung Cancer
The purpose of this research study is to look at how effective two drugs, nivolumab and ipilimumab, are for people with non-small lung cancer that has metastasized (has spread to other parts of the body) and to see what effects…
- Trial name
- ATLAS (NCT04966676)
- Testing
- cfDNA blood test, Nivolumab, Ipilimumab
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- University Health Network, Toronto
Breast Cancer Stage III, HER2-positive Metastatic Breast Cancer
Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors
The objective of this study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of BL-M17D1 in patients with HER2-Expressing or HER2-Mutant Advanced or Metastatic Solid Tumors.
- Conditions
- Breast Cancer Stage III, HER2-positive Metastatic Breast Cancer, Unresectable Breast Carcinoma, Her2-Positive
- Trial name
- NCT06714617
- Testing
- BL-M17D1
- Where
- 9 sites in United States
- Volunteers
- 3 people
- Sponsor
- SystImmune Inc.
Non-small-cell Lung Cancer (NSCLC) Stage IIIb/IV
Vaccine Therapy in Treating Patients With Non-Small Cell Lung Cancer (NSCLC) Stages IIIB/IV
The purpose of this study is to determine whether the recombinant human EGF-rP64K/Montanide ISA 51 vaccine is safe, immunogenic and effective in the treatment of stage IIIb/IV non-small-cell lung cancer (NSCLC).
- Trial name
- NSCLC (NCT00516685)
- Testing
- Recombinant Human rEGF-P64K/Montanide Vaccine
- Where
- 10 sites in Malaysia
- Volunteers
- 230 people
- Sponsor
- Bioven Sdn. Bhd.
Carcinoma, Non-Small-Cell Lung
M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)
The main purpose of the study was to evaluate the safety and tolerability of M7824 in combination with chemotherapy.
- Trial name
- NCT03840915
- Testing
- Cisplatin, Carboplatin, Pemetrexed
- Where
- 19 sites in United States, Belgium and 1 more
- Volunteers
- 70 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Lung Cancer
Validation of a Kinetic Model of Erlotinib
Several arguments are in favor of a therapeutic monitoring for the erlotinib, therefore, a pharmacokinetic (PK) has been prepared using data from the literature.
- Trial name
- NCT02904850
- Testing
- group of patients
- Where
- France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Strasbourg, France
Non-small Cell Lung Cancer
An Exploratory Study of Herombopag for Thrombocytopenia Induced by Chemotherapy Combined With Immunotherapy in NSCLC
The purpose of this study is to explore the safety and efficacy of herombopag olamine tablets for thrombocytopenia induced by chemotherapy combined with immunotherapy in non-small cell lung cancer
- Trial name
- NCT05252091
- Testing
- herombopag olamine tablets
- Volunteers
- 30 people
- Sponsor
- Henan Cancer Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.